-
State Food and Drug Administration: Artificial blood vessels approved for marketing
Time of Update: 2023-01-06
Recently, the State Medical Products Administration approved the registration of artificial blood vessels of innovative products produced by Jiangsu Baiyouda Life Science and Technology Co.
docxRecently, the State Medical Products Administration approved the registration of artificial blood vessels of innovative products produced by Jiangsu Baiyouda Life Science and Technology Co.
-
New developments in the FDA's Quality Management Maturity Program
Time of Update: 2023-01-06
The meeting began with the topic of drug shortages, pointing out that one of the main reasons for drug shortages is quality problems, and the root cause of quality problems is that the market does not recognize and reward manufacturers with "mature quality systems" that focus on continuous improvement and early detection of supply chain problems, so it is recommended to develop a rating system to incentivize pharmaceutical manufacturers to invest in QMM.
-
PI3K's two heavens of ice and fire: delisting in Europe and the United States, and listing in China
Time of Update: 2023-01-06
In 2018, Secura's PI3K inhibitor, Duvelisib, was fully approved by the FDA for the treatment of adult patients with relapsed/refractory CLL/SLL who have received at least two upfront therapies, and also received accelerated approval for the third-line treatment of follicular lymphoma.
-
In November, a number of pharmaceutical companies announced that related products won the first imitation!
Time of Update: 2023-01-06
Recently, the website of the State Food and Drug Administration shows that Changfeng Pharmaceutical's nitrosestine fluticasone nasal spray (azelastine propionate nasal spray) has been approved for imitation of Class 3 production, becoming the first approved enterprise for this product.
-
In November, a number of pharmaceutical companies announced that related products won the first imitation!
Time of Update: 2023-01-06
Recently, the website of the State Food and Drug Administration shows that Changfeng Pharmaceutical's nitrosestine fluticasone nasal spray (azelastine propionate nasal spray) has been approved for imitation of Class 3 production, becoming the first approved enterprise for this product.
-
Heavy! The world's first new drug to delay type 1 diabetes was approved by the FDA
Time of Update: 2023-01-06
The approval is based on a randomized, double-blind, event-driven, placebo-controlled trial of 76 patients with stage 2 diabetes who evaluated the safety and efficacy of Teplizumab.
The approval is based on a randomized, double-blind, event-driven, placebo-controlled trial of 76 patients with stage 2 diabetes who evaluated the safety and efficacy of Teplizumab.
-
Heavy! The world's first new drug to delay type 1 diabetes was approved by the FDA
Time of Update: 2023-01-06
The approval is based on a randomized, double-blind, event-driven, placebo-controlled trial of 76 patients with stage 2 diabetes who evaluated the safety and efficacy of Teplizumab.
The approval is based on a randomized, double-blind, event-driven, placebo-controlled trial of 76 patients with stage 2 diabetes who evaluated the safety and efficacy of Teplizumab.
-
Pharmaceutical companies are accelerating the development of new indications, and competition in this area is fierce
Time of Update: 2023-01-06
At present, large pharmaceutical companies at home and abroad attach great importance to the development of new indications of innovative drugs, and are continuously expanding the field of drug use.
-
Pharmaceutical companies are accelerating the development of new indications, and competition in this area is fierce
Time of Update: 2023-01-06
At present, large pharmaceutical companies at home and abroad attach great importance to the development of new indications of innovative drugs, and are continuously expanding the field of drug use.
-
Exclusive interview with Ren Feng: Behind the $1.2 billion major cooperation, why is Insilico favored by Sanofi?
Time of Update: 2023-01-06
Arterial New Medicine learned for the first time that on November 8, Insilico, a clinical-stage drug discovery company driven by artificial intelligence (AI), announced a multi-year drug development collaboration with Sanofi that will last for many years and target multiple targets.
-
Advancing Childhood Cancer Research: The Impact and Significance of the RACE Act
Time of Update: 2023-01-06
4 All stakeholders can contribute to the RACE Act4 All stakeholders can contribute to the RACE ActAll clinical trial stakeholders – including regulators, patients and parents, oncology drug developers, pharmaceutical companies and policymakers – will play a key role in achieving the goals of the RACE Act. The RACE Act promotes systematic further collaboration, promotion, sharing, and connectivity in oncology and pediatric scientific research.
-
How to extend the life cycle of the original drug product? Rely on these three points
Time of Update: 2023-01-06
The two new pharmaceutical uses in the narrow and broad sense can not only obtain legal protection extension, that is, the extension of the term of product protection by obtaining patent authorization, but also administrative protectionAdalimumab injection is the world's first fully human anti-tumor necrosis factor monoclonal antibody approved for marketing.
-
This week, many domestic pharmaceutical companies have ushered in new clinical progress in new drugs!
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】In the increasingly crowded R&D track and increasingly fierce competition, a large number of pharmaceutical companies are actively responding to national policies
-
This week, many domestic pharmaceutical companies have ushered in new clinical progress in new drugs!
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】In the increasingly crowded R&D track and increasingly fierce competition, a large number of pharmaceutical companies are actively responding to national policies
-
Hundreds of millions of dollars at every turn, involving thousands of pharmacies. Major cross-provincial cases uncover the illegal interest chain of medical insurance "water stealers"
Time of Update: 2023-01-06
In the process of clearing up the "reflux medicines", the Nanchang police took a suspicious "drug dealer" at the entrance of the hospital as the line, and after eight months of continuous combat, finally overturned a criminal network involving nearly 100 people from 22 provinces and cities, involving more than 200 million yuan in the case of buying and selling medical insurance drugs.
-
On the second anniversary of the "dual carbon" goal, how can Chinese pharmaceutical companies move towards carbon neutrality?
Time of Update: 2023-01-06
For Chinese pharmaceutical companies, judging and adapting to the specific impacts of climate change on their business and industrial chains, and promoting the sustainability of carbon reduction measures by improving resilience and resilience, is an important starting point for them to achieve their long-term carbon neutrality goals.
-
China's Healthcare Investment and Financing "Ten Years of Great Changes"
Time of Update: 2023-01-06
According to the statistics of InvestGO database, the investment trend in the medical and health field has generally increased since 2013, with the cumulative number of events in the past 10 years approaching 14,000, the primary market financing amount of 970 billion yuan, and the secondary market fundraising exceeded 1.
-
The moment of change: when more and more innovative pharmaceutical companies come out of the involvement
Time of Update: 2023-01-06
On November 10, APL-1401, the world's first investigational drug for the treatment of IBD (inflammatory bowel disease) with neurotransmitters, was approved by the FDA for clinical trial, which is a microcosm of the upward process of the innovative drug industry.
-
Roche, Takeda, Sanofi, Novo Nordisk, Organon
Time of Update: 2023-01-06
Novo Nordisk joins hands with Shanghai Pharmaceutical Holdings to promote intelligent drug logistics and warehousingNovo Nordisk joins hands with Shanghai Pharmaceutical Holdings to promote intellige
-
Innovative drugs are facing a new round of "big tests", and a number of domestic innovative drugs are rushing to enter
Time of Update: 2023-01-06
Among them, Zhongke Tuola announced on November 4 that the company's new small molecule inhibitors TR115 tablets and TR64 tablets with independent intellectual property rights were approved by the NMPA Drug Evaluation Center on November 4, 2022, and agreed to carry out clinical trials for non-Hodgkin lymphoma and advanced malignant solid tumors.
